Table 1.
Patient demographic and clinical characteristics
| ToxNav (n = 466) | No-ToxNav (n = 1556) | Difference (p-value) | |
|---|---|---|---|
| Female | 218 (47%) | 900 (58%) | −11 p.p. (0.000) |
| Race | (0.136) | ||
| Caucasian | 304 (65%) | 1079 (69%) | −4 p.p |
| Asian | 6 (1%) | 28 (2%) | −1 p.p. |
| African | 2 (0%) | 15 (1%) | −1 p.p. |
| Mixed | 0 (0%) | 3 (0%) | 0 p.p. |
| Other/unknown | 154 (33%) | 432 (28%) | 5 p.p. |
| Tumour site | (0.000) | ||
| Upper GI | 71 (15%) | 299 (19%) | −4 p.p. |
| Lower GI | 167 (36%) | 724 (47%) | −11 p.p. |
| Breast | 117 (25%) | 382 (25%) | 0 p.p. |
| Other | 35 (8%) | 132 (8%) | 0 p.p. |
| Missing | 76 (16%) | 19 (1%) | 15 p.p. |
| Mean age at start FU | 61.3 (12.9) | 60.1 (12.9) | −1 (0.0643) |
| Mean FU months (SD) n | 13.8 (6.2) 391 | 24.6 (13.0) 1470 | −11 (0.0000) |
| Mean chemo cycles (SD) n | 3.8 (2.9) | 5.1 (7.8) | 1.3 (0.0401) |
| Total deaths | 95 (20%) | 490 (32%) | −12 p.p. (0.000) |
| Deaths within 30 days of chemo | 7 (2%) | 35 (2%) | 0 p.p. (0.321) |
| Deaths due to Capecitabine/5FU | 1 (0.2%) | 10 (0.6%) | 0 p.p |
| Cardiac deaths due to Capecitabine/5FU | 1 (0.2%) | 2 (0.1%) | 0 p.p |